Researchers have demonstrated that inebilizumab reduced the risk of symptoms by 87 percent in patients with the rare affliction known as immunoglobulin G4-related disease (IgG4-RD).

DEAR DR. ROACH: A few months ago, you wrote about the benefits of the shingles vaccine. At 63, I’m one of the 1% who has ...